ZOONO Group Ltd (ASX:ZNO) Share Price Drops: Key Reasons Explained

Sonal Goyal

23 October 2026 02:47 PM AEDT

ZOONO Group Ltd (ASX:ZNO) Share Price Drops: Key Reasons Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

ZOONO Group Ltd (ASX:ZNO) was trading at A$0.044, down 12.00%, during the 23 October 2026 trading session.
On 23 October 2026, the company announced a one-for-ten non-renounceable rights issue at A$0.039 per share to raise up to A$1,609,226.
The company also said it completed a A$250,000 Placement of 6,410,256 shares at A$0.039 on 23 October 2026.

ZOONO Group Ltd (ASX:ZNO) was trading at A$0.044 during the 23 October 2026 trading session, down 12.00%. By comparison, the S&P/ASX 200 (XJO) was at 8,760.50, down 0.37% (32.70 points) at 1:16 pm AEDT, meaning ZOONO's move was far wider than the benchmark's. ZOONO describes itself as a global biotech company that develops, manufactures and distributes antiviral and antibacterial solutions, and it is headquartered in New Zealand. The move came on the same day the company released an ASX announcement, dated 23 October 2026, detailing a non-renounceable rights issue and a completed placement.

Latest Developments

23 October 2026: Non-Renounceable Rights Issue

On 23 October 2026, ZOONO announced a pro-rata non-renounceable rights issue of one new share for every ten shares held by eligible shareholders registered at the record date. The issue price is A$0.039 per share, and the company said the offer would raise up to A$1,609,226 before costs. The announcement set out that 41,262,202 shares would be issued under the offer.

The company said all shareholders on the register at 7.00pm AEDT on 29 October 2026, other than those where it would not be lawful to make the offer, will be able to participate. It also said Managing Director and major Shareholder Paul Hyslop, along with other directors who own shares, intend to participate, and that shareholders will have the opportunity to apply for any unplaced shares, referred to as the shortfall.

Placement Completed

In the same announcement, ZOONO said it had completed a placement on 23 October 2026 of 6,410,256 shares at A$0.039 per share to an existing shareholder, raising A$250,000. The placement shares are included in the shares currently on issue and will participate in the rights issue.

Intended Use of Funds

According to the announcement, funds from the rights issue will be used for the shelf-life extension project, including in China and India, patents and IP protection, directors' fees, overheads and corporate costs, Working Capital and the expenses of the offer.

Indicative Timetable

The company published an indicative timetable. The ex-date is 28 October 2026 and the Record Date is 29 October 2026. The offer opens on 3 November 2026 and is scheduled to end on 17 November 2026 at 5.00pm AEDT, with Quotation of the new shares scheduled for 25 November 2026. The company noted that the dates are indicative and subject to change, and that directors reserve the right to extend the offer period.

About ZOONO Group Ltd

ZOONO Group Ltd develops, manufactures and distributes what it describes as scientifically validated, long-lasting and environmentally friendly antiviral and antibacterial solutions. Its product range includes sprays, wipes and foams suited to skin care, surface sanitisers and mould remediation treatments. The products are based on the Zoono molecule, which the company says bonds to any surface and inhibits the ability of microbes, including bacteria, viruses, algae, fungi and mould, to bind to it.

With its strategic partner OSY Group Limited, the company developed a ZXT specialty range and, according to its announcement, has continued commercialising shelf-life extension products and technologies across multiple geographies and produce categories. ZOONO says its products have received numerous regulatory approvals.

Related Sector Context

ZOONO operates in the antimicrobial and hygiene products segment, which sits between health, consumer products and food-related applications through its shelf-life extension work. A rights issue differs from a placement in that it is offered to existing shareholders in proportion to their holdings. The S&P/ASX 200 benchmark was down 0.37% at 1:16 pm AEDT on 23 October 2026.

Risks to Weigh In

The rights issue is non-renounceable and the final amount raised depends on shareholder take-up and any shortfall.
The company's announced timetable is indicative only and subject to change, including possible extension of the offer period.
The offer would increase shares on issue from 412,622,020 to 453,884,222 if fully taken up.
The stated uses of funds include working capital, overheads and corporate costs alongside the shelf-life extension project.

Catalysts on Watch

The ex-date of 28 October 2026 and the record date of 29 October 2026.
Despatch of the offer document and opening of the offer on 3 November 2026.
The scheduled end of the offer on 17 November 2026.
Announcement of results before 12.00pm AEDT on 24 November 2026.
Quotation of the new shares, scheduled for 25 November 2026.

Where Things Stand

ZOONO shares were trading at A$0.044, down 12.00%, during the 23 October 2026 session, and the company released its rights issue and placement announcement the same day. The rights issue is priced at A$0.039 per share and aims to raise up to A$1,609,226 before costs, with a timetable running through to quotation on 25 November 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.